I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Completed

• Conditions: Neuroblastoma; Pheochromocytoma

• Registration Number: NCT00590096
• Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Brief Summary

I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Detailed Description

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

Study Timeline

• Study Start: 1991-01
• Status Verified: 2007-01
• Study First Submitted: 2007-12-27
• Study First Submitted QC: 2007-12-27
• Study First Posted: 2008-01-10
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Last Update Submitted: 2009-08-24
• Last Update Posted: 2009-08-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1380

Inclusion Criteria

• Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Exclusion Criteria

• Pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified